Rating: Overweight

Executive Summary: Initiate a phased 2% position in NVDA at $210 with a hard stop at $185. Place remaining 2-3% allocation on the sidelines with limit orders at $195, $190, and $185 to scale in on deeper pullbacks. This structure captures the extraordinary fundamental opportunity ($81.6B quarterly revenue, 71.5% net margins, 16.7x forward P/E, PEG 0.66) while respecting the genuine technical deterioration (MACD down 59% from peak, RSI below 50, price below VWMA and Bollinger middle band) that makes a full 4-5% position premature. Time horizon: 3-6 months through next earnings (late August). If the Iran deal catalyst resolves favorably, expect re-rating toward $240-260. If technical breakdown occurs, the $185 stop limits portfolio drawdown to ~0.5%.

Investment Thesis: The Aggressive Analyst is correct on the core fundamental case: $81.6B quarterly revenue (+85% YoY, +20% QoQ accelerating sequentially), 71.5% net margins, $48.6B quarterly free cash flow, a net cash balance sheet ($80.6B cash vs $12.4B debt), forward P/E of 16.7x, and a PEG ratio of 0.66. This is a genuinely rare valuation anomaly — a monopolistic business with 80-95% AI GPU market share, 114% ROE, and a CUDA ecosystem moat trading below the S&P 500's P/E while growing at 85%. The Aggressive Analyst is also right that the rotation into Lumentum/AMAT is a bullish broadening of the AI ecosystem, not a rejection of NVDA — the entire AI capex cycle depends on NVDA silicon.

However, the Conservative Analyst is equally correct that the technical signals are too dangerous to ignore at full position sizing. MACD has lost 59% of its momentum while price has only corrected 10% — that's a textbook divergence that historically precedes deeper corrections. RSI washing out from 76 to 49 in 11 sessions without corresponding price decline signals institutional distribution, not a healthy consolidation. Price sits below VWMA ($220), the 10-day EMA, and the Bollinger middle band. The 50 SMA at $199 is not "pillow-soft support" — with recent buyers underwater at $220, overhead supply will resist any bounce. A test of the 200 SMA at $187.64 (11% drawdown) is a realistic scenario.

The Neutral Analyst provides the optimal synthesis: neither a full Buy (which dismisses genuine technical risk) nor a Hold (which forfeits exposure to a 0.66 PEG company accelerating QoQ growth) is correct. The documented prior lessons reinforce this — the 2026-05-27 NVDA Overweight (-1.5% alpha) failed because technical distribution severity was underweighted relative to valuation support; the 2026-05-23 Overweight (-1.4% alpha) failed because a support zone was conflated with a reversal trigger. Both lessons are explicitly priced here: reduced initial sizing (2% vs 4-5%) and wider defendable tranches ($195, $190, $185 — not $210, $205, $200) reflect that the technical momentum is genuinely against us in the short term.

The three-macro-if risk the Aggressive Analyst embraces (Iran deal, energy drop, Fed pivot) is real — El-Erian's recession warning at current gas prices and the binary nature of Iran negotiations mean the next 2-4 weeks carry elevated tail risk. Scaling in over price levels (not just days) ensures we buy on confirmed support, not hope. The 2026-05-16 Hold (-4.1% alpha) lesson — that a consensus Hold should default to smaller sizing — is applied here by taking a partial Overweight rather than a full Buy. If the Iran deal resolves favorably and the VWMA is recaptured on volume, the remaining 2-3% can be deployed at a higher price with confirmed momentum, which is a better risk than front-running the binary event at full size.

Price Target: 260.0

Time Horizon: 3-6 months (through next earnings in late August)